Literature DB >> 23135514

Defeating dengue: a challenge for a vaccine.

.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23135514     DOI： 10.1038/nm.2997

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.

Authors:  Daniel H Libraty; Timothy P Endy; Huo-Shu H Houng; Sharone Green; Siripen Kalayanarooj; Saroj Suntayakorn; Wanya Chansiriwongs; David W Vaughn; Ananda Nisalak; Francis A Ennis; Alan L Rothman
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

2.  Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization.

Authors:  Annette A Kraus; William Messer; Laura B Haymore; Aravinda M de Silva
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

3.  Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Authors:  F Guirakhoo; R Weltzin; T J Chambers; Z X Zhang; K Soike; M Ratterree; J Arroyo; K Georgakopoulos; J Catalan; T P Monath
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Dengue vaccine development: a 75% solution?

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

5.  HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais.

Authors:  H A F Stephens; R Klaythong; M Sirikong; D W Vaughn; S Green; S Kalayanarooj; T P Endy; D H Libraty; A Nisalak; B L Innis; A L Rothman; F A Ennis; D Chandanayingyong
Journal:  Tissue Antigens       Date:  2002-10

6.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

Review 7.  Immune response to dengue virus and prospects for a vaccine.

Authors:  Brian R Murphy; Stephen S Whitehead
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 8.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

9.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

Review 10.  Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.

Authors:  Theodore C Pierson; Daved H Fremont; Richard J Kuhn; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023
  10 in total
  6 in total

1.  Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.

Authors:  Wen-Yang Tsai; Anna Durbin; Jih-Jin Tsai; Szu-Chia Hsieh; Stephen Whitehead; Wei-Kung Wang
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

Review 2.  Mouse models to study dengue virus immunology and pathogenesis.

Authors:  Raphaël M Zellweger; Sujan Shresta
Journal:  Front Immunol       Date:  2014-04-10       Impact factor: 7.561

3.  Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.

Authors:  Raphaël M Zellweger; Robyn Miller; William E Eddy; Laura J White; Robert E Johnston; Sujan Shresta
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

4.  High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

Authors:  Wen-Yang Tsai; Chih-Yun Lai; Yi-Chieh Wu; Hong-En Lin; Carolyn Edwards; Amonrat Jumnainsong; Srisakul Kliks; Scott Halstead; Juthathip Mongkolsapaya; Gavin R Screaton; Wei-Kung Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

5.  Dengue virus type 3 adaptive changes during epidemics in São Jose de Rio Preto, Brazil, 2006-2007.

Authors:  Christian Julian Villabona-Arenas; Adriano Mondini; Irene Bosch; Diane J Schimdt; Diane Schimitt; Carlos E Calzavara-Silva; Paolo M de A Zanotto; Maurício L Nogueira
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

6.  Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.

Authors:  Hui Zhao; Tao Jiang; Xi-Zhen Zhou; Yong-Qiang Deng; Xiao-Feng Li; Shui-Ping Chen; Shun-Ya Zhu; Xi Zhou; E-De Qin; Cheng-Feng Qin
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.